Eschner W - Search Results

1

Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma.

Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H. Sudbrock F, et al. Among authors: eschner w. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1279-90. doi: 10.1007/s00259-010-1391-7. Epub 2010 Feb 24. Eur J Nucl Med Mol Imaging. 2010. PMID: 20179922

2

PROLARA: prognosis-based lifetime attributable risk approximation for cancer from diagnostic radiation exposure.

Eschner W, Schmidt M, Dietlein M, Schicha H. Eschner W, et al. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):131-5. doi: 10.1007/s00259-009-1221-y. Eur J Nucl Med Mol Imaging. 2010. PMID: 19662409

3

Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H. Schmidt M, et al. Among authors: eschner w. Nuklearmedizin. 2006;45(4):145-51; quiz N39-40. Nuklearmedizin. 2006. PMID: 16964339

4

[Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].

Sudbrock F, Eschner W, Schmidt M, Simon T, Hero B, Schicha H. Sudbrock F, et al. Among authors: eschner w. Nuklearmedizin. 2006;45(6):254-61. Nuklearmedizin. 2006. PMID: 17149494 German.

5

Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.

Schmidt M, Bollschweiler E, Dietlein M, Mönig SP, Kobe C, Vallböhmer D, Eschner W, Hölscher A, Schicha H. Schmidt M, et al. Among authors: eschner w. Eur J Nucl Med Mol Imaging. 2009 May;36(5):735-44. doi: 10.1007/s00259-008-1011-y. Epub 2008 Dec 19. Eur J Nucl Med Mol Imaging. 2009. PMID: 19096843

6

Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?

Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, Dietlein M, Schicha H. Kobe C, et al. Among authors: eschner w. Nucl Med Commun. 2010 Mar;31(3):201-5. doi: 10.1097/MNM.0b013e328333d303. Nucl Med Commun. 2010. PMID: 19907353

7

Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?

Eschner W, Kobe C, Schicha H. Eschner W, et al. Z Med Phys. 2011 Dec;21(4):258-65. doi: 10.1016/j.zemedi.2011.04.006. Epub 2011 Jun 29. Z Med Phys. 2011. PMID: 21719262

8

Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapy.

Kahraman D, Keller C, Schneider C, Eschner W, Sudbrock F, Schmidt M, Schicha H, Dietlein M, Kobe C. Kahraman D, et al. Among authors: eschner w. Clin Endocrinol (Oxf). 2012 Feb;76(2):297-303. doi: 10.1111/j.1365-2265.2011.04204.x. Clin Endocrinol (Oxf). 2012. PMID: 21854403

9

Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, Drzezga A, Wild M. Hohberg M, et al. Among authors: eschner w. Mol Imaging Biol. 2016 Jun;18(3):437-45. doi: 10.1007/s11307-016-0942-0. Mol Imaging Biol. 2016. PMID: 26920354

10

Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?

Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H. Kobe C, et al. Among authors: eschner w. Nuklearmedizin. 2008;47(1):13-7. Nuklearmedizin. 2008. PMID: 18278207

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters